BNP PARIBAS ARBITRAGE/CALL/BIONTECH ADR/90/0.1/20.12.24 Share Price

Warrant

P20SY3

NLBNPIT20SY3

Real-time Borsa Italiana 06:41:59 27/06/2024 pm IST
0.668 EUR +4.21% Intraday chart for BNP PARIBAS ARBITRAGE/CALL/BIONTECH ADR/90/0.1/20.12.24
Current month-63.89%
1 month-57.83%
Date Price Change
27/24/27 0.668 +4.21%
26/24/26 0.641 -12.55%
25/24/25 0.733 -13.56%
24/24/24 0.848 +10.42%
21/24/21 0.768 -9.22%

Real-time Borsa Italiana

Last update June 27, 2024 at 06:41 pm IST

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying BIONTECH SE
IssuerLogo Issuer BNP Paribas BNP Paribas
P20SY3
ISINNLBNPIT20SY3
Date issued 18/03/2024
Strike 90 $
Maturity 20/12/2024 (176 Days)
Parity 10 : 1
Emission price-
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 2.07
Lowest since issue 0.628
Delta0.47x
Omega 5.431
Premium17.72x
Gearing11.56x
Moneyness 0.9169
Difference Strike 7.48 $
Difference Strike %+8.31%
Spread 0.178
Spread %23.58%
Theoretical value 0.6660
Implied Volatility 40.42 %
Total Loss Probability 63.91 %
Intrinsic value 0.000000
Present value 0.6660
Break even 97.14 €
Theta-0.02x
Vega0.02x
Rho0.01x

Company Profile

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Sector
-
More about the company

Ratings for BioNTech SE

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: BioNTech SE

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
77.26 EUR
Average target price
103.5 EUR
Spread / Average Target
+33.99%
Consensus
  1. Stock Market
  2. Warrants
  3. P20SY3 Warrant